BioTuesdays

Category - Markets

Vectiv-Bio
Markets

SVB Leerink starts VectivBio at OP; PT $28

SVB Leerink launched coverage of VectivBio Holding AG (NASDAQ:VECT) with an “outperform” rating and $28 price target. The stock closed at $15.21 on May 3. VectivBio is focused on developing treatments for severe rare...

May 4, 2021
Lucira-Health-Logo
Markets

WB cuts Lucira Heath to market perform

William Blair downgraded Lucira Health (NASDAQ:LHDX) to “market perform,” citing changes to the testing market that have played out over the last couple of months coupled with lack of demand for the company’s at-home...

May 4, 2021
ProQR
Markets

Stifel starts ProQR Therapeutics at buy; PT $20

Stifel initiated coverage of ProQR Therapeutics N.V. (NASDAQ:PRQP) with a “buy” rating and price target of $20. The stock finished at $6.22 on April 30. “As a clinical-stage company with demonstrated proof-of-concept...

May 3, 2021
AVROBIO
Markets

SVB Leerink cuts AVROBIO PT to $10 from $18

SVB Leerink reduced its price target for AVROBIO (NASDAQ:AVRO) to $10 from $18 but maintained its “market perform” rating after the company announced that it may no longer pursue an accelerated approval pathway for AVR...

May 3, 2021
Clene-Nanomedicine
Markets

Cantor starts Clene at OW; PT $22

Cantor Fitzgerald launched coverage of Clene (NASDAQ:CLNN) with an “overweight” rating and 12-month price target of $22. The stock closed at $9 on April 30. Clene is a neuro-innovator that is developing drugs to enhance...

May 3, 2021
DermTech-Logo
Markets

BTIG starts DermTech at buy; PT $53

BTIG initiated coverage of DermTech (NASDAQ:DMTK) with a “buy” rating and $53 price target. The stock closed at $42.05 on April 30. DermTech provides genomic diagnostic testing for various skin diseases and conditions...

May 3, 2021
SioGene-Therapies
Markets

HCW starts Sio Gene Therapies at buy; PT $8

H.C. Wainwright initiated coverage of Sio Gene Therapies (NASDAQ:SIOX) with a “buy” rating and price target of $8. The stock closed at $2.70 on April 29. Sio is a gene therapy company with significant experience and...

April 30, 2021
Cardiol Therapeutics
Markets

Raymond James ups Cardiol Therapeutics to OP from MP

Raymond James upgraded Cardiol Therapeutics (TSX:CRDL) to “outperform” from “market perform,” citing enrollment of the first patient in a Phase 2/3 clinical trial investigating the cardioprotective properties of...

April 28, 2021
Akouos
Markets

HCW starts Akouos at buy; PT $25

H.C. Wainwright launched coverage of Akouos (NASDAQ:AKUS) with a “buy” rating and $25 price target. The stock closed at $15.03 on April 26. Akouos is a precision genetic medicine company focused primarily on the...

April 27, 2021
Xenon Pharma
Markets

Stifel ups Xenon Pharma PT to $31 from $23

Stifel raised its price target for Xenon Pharmaceuticals (NASDAQ:XENE) to $31 from $23, ahead of Phase 2b focal seizure data expected in the third quarter this year. The stock closed at $17.97 on April 23. “From our...

April 26, 2021